 Cookies help identify the right message.

We would like to use anonymous analytics cookies to help improve our website experience. View our cookie policy.

Skip to content
Pipeline Investors News Join us Contact

Contact Us

  • +44 [0] 20 4551 8888
  • contact@tangramtx.com
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X
Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.
  • About[+]
    • About[+]
      • Why Tangram?Explore more about how and why Tangram Therapeutics exists.
      • LeadershipDiscover the people leading the way in relentless medicine discovery.
  • Pipeline
  • Our science[+]
    • Our Science[+]
      • Our ApproachWe reduce the risks of making impactful medicine a reality.
      • LLibraConnecting extensive data and information with AI, powering GalOmic drug discovery.
      • GalOmicEnabling the generation of Tangram Therapeutics' potent and long-acting RNAi medicines.
  • Investors
  • News
  • Join us
  • Contact
Menu
Press release

Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

30 March 2026

  • Press release

Notification of Full Year Results Date

Feb 20, 2019

  • Press release

Research Collaboration Agreement with Novo Nordisk

Dec 10, 2018

  • Press release

E-therapeutics and C4X Collaboration

Dec 6, 2018

  • Press release

Drug Discovery Innovation Programme Presentation

Nov 29, 2018

  • Press release

e-therapeutics to present at BioCentury Summit

Nov 12, 2018

  • Press release

Interim Results for six months ended 31 July 2018

Oct 4, 2018

  • Press release

Notice of Interim Results

Sep 17, 2018

  • Press release

Collaboration with C4X Discovery Holdings PLC

May 1, 2018

  • Press release

Full Year Results

Mar 27, 2018

  • Press release

Notification of Full Year Results Date

Mar 12, 2018

  • Press release

E-Therapeutics enters two AI collaborations

Jan 15, 2018

  • Press release

Appointment of Director

Nov 1, 2017

  • Press release

Interim Results for the 6 Months Ended 31 July 2017

Sep 26, 2017

  • Press release

Notice of Results

Sep 5, 2017

  • Press release

Edison issues update on e-Therapeutics (ETX)

Jul 27, 2017

  • Press release

Outcome of Strategic Review and Future Plans

Jul 24, 2017

  • Press release

Final Results

Apr 19, 2017

  • Press release

New CEO Commences at e-Therapeutics

Apr 6, 2017

  • Press release

Notification of Full Year Results Date

Apr 6, 2017

  • Press release

Directorate Change

Feb 16, 2017

  • Press release

Appointment of CEO

Jan 9, 2017

RELENTLESS
CREATIVITY

London HQ

  • Floor 4, 4 Kingdom Street
    Paddington Central London W2 6BD

[LOCAL TIME]

Company

  • About
  • Our Approach
  • Pipeline
  • Investors
  • News
  • Careers
  • Leadership
  • Contact

© 2026 Tangram Therapeutics. Brand and website by UnitedUs. V9.3

  • Press Release Sign Up
  • Sitemap
  • Accessibility
  • Privacy
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X

OUR TRANSFORMATION INTO TANGRAM

Pioneering advancements in drug development takes steadfast persistence. A ceaseless evolution of understanding and innovation. That’s why E-Therapeutics has transformed into Tangram Therapeutics. The new brand embodies the expedited exploration needed to unlock life-transforming RNAi medicines faster. Breaking conventions of slow science, Tangram makes sense of patterns to find new answers. Our transformation into Tangram reveals the robust focus necessary for relentless medicine discovery.

Discover our new identity